Latest News for VTAK
FORT MILL, S.C., March 06, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK), a pioneer in medical technology for the cardiac electrophysiology market, today announced that its LockeT suture retention device will be highlighted during live procedural cases at the International Symposium of Left Atrial Appendage 2026 conference. The event, co-hosted by the Academy for Continued Healthcare…
Catheter Precision (NYSE: VTAK) shares are down on Thursday as the company announced a strategic divestiture of its non-core assets.
Upfront Cash, Equity Participation and Tiered Royalty Structure Providing Long-Term Revenue Upside Upfront Cash, Equity Participation and Tiered Royalty Structure Providing Long-Term Revenue Upside
New York, NY, Feb. 17, 2026, – PRISM MediaWire (Press Release Service – Press Release Distribution) – Creatd, Inc. (OTCQB: CRTD) announced that Catheter Precision, Inc. (NYSE American: VTAK) has acquired a 20% equity interest in Fly Flyte, Inc., its subsidiary, through a secondary purchase from an existing shareholder.
Strategic Partnership: Creatd expanded Fly Flyte's investor network by adding NYSE-listed VTAK as an investor in its subsidiary. Portfolio Expansion: Creatd continues advancing its portfolio strategy through multiple active acquisition discussions.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for VTAK.
U.S. House Trading
No House trades found for VTAK.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.